top of page

EHA 2026: Karyopharm is hoping to add two new indications for selinexor over the near term - they just presented the phase 3 for the first one, myelofibrosis, at ASCO with an encore at EHA

  • 4 hours ago
  • 1 min read

CEO Richard Paulson walks us through the unmet need in myelofibrosis and the phase three data, which almost doubled the percent of patients achieving SVR35 (a measure of spleen volume reduction) at Week 24, one of the trial's co-primary endpoints. The company will also have a key pivotal trial readout in endometrial cancer sometime in the middle of this year.



Join the BiotechTV mailing list

Thanks for subscribing!

Follow BiotechTV

  • Twitter

@BiotechTV

  • LinkedIn

BiotechTV

  • Facebook

BiotechTVHQ

  • TikTok

@BiotechTV

  • Instagram

@BiotechTVHQ

Also look for unique social pages for BiotechTV U.

Sponsor Spotlight

HSBC_IB_Stacked_logo.png

HSBC Innovation Banking's dedicated sector experts possess in-depth knowledge of the technology, life science and healthcare economies. With access to an extensive global network, we can help you fuel growth through venture capital and corporate investors, industry influencers, customers, and global opportunities.

​

​Through our interconnected innovation hubs in the US, UK, Israel and Hong Kong, our experts are supporting the world’s innovation economy – both clients and their investors to help them meet their growth goals.

Learn more

bottom of page